<DOC>
	<DOCNO>NCT02725593</DOCNO>
	<brief_summary>A trial patient age 10-24 year type 2 diabetes mellitus evaluate comparative efficacy safety dapagliflozin Placebo</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Dapagliflozin Patients With Type 2 Diabetes Mellitus Aged 10-24 Years</brief_title>
	<detailed_description>A 24 Week , Multicenter , Randomized , Double-Blind , Parallel Group , Phase 3 Trial 28 Week Long Term Safety Extension Period Evaluating Safety Efficacy Dapagliflozin 10 mg T2DM Patients age 10-24 year</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria 1 . Provision inform consent prior studyspecific procedure 2 . Males Females , age 10 year age , include 25 year age time randomization 3 . Previously diagnose type 2 diabetes least 2 month WHO/ADA diagnostic criterion 4 . HbA1c &gt; = 6.5 % &lt; = 11 % obtain screen visit 5 . Currently diet exercise stable dose metformin ( least 1000 mg daily ) minimum 8 week , stable dose insulin minimum 8 week , stable combination metformin ( least 1000 mg daily ) insulin minimum 8 week prior screen 6 . FPG &lt; =255 mg/dL ( &lt; = 14.2 mmol/L ) obtain screen visit 1 . Previous diagnosis Type 1 diabetes 2 . Diabetes ketoacidosis ( DKA ) within 6 month screen 3 . Current use follow medication treatment diabetes , use within specify timeframe prior screen main study : Eight week : sulfonylurea , alpha glucosidase inhibitor , metiglinide , injectable incretins incretin mimetics antidiabetes medication otherwise specify Sixteen week : thiazolidinediones Any previous history current use SGLT2 inhibitor , include dapagliflozin 4 . Initiation discontinuation prescription nonprescription weight loss drug within 8 week screen . Use prescription nonprescription weight loss drug must stable study 5 . Pregnant , positive serum pregnancy test , plan become pregnant clinical trial , breastfeed 6 . History unstable rapidly progressive renal disease 7 . History unresolved vesicoureteral reflux 8 . Replacement chronic systemic corticosteroid therapy , define dose systemic corticosteroid take &gt; 4 week within 3 month prior Day 1 visit . Note : Topical , nasal , inhaled corticosteroid allow 9 . Abnormal renal function , define subject &lt; 18 year age estimate glomerular filtration rate ( eGFR ) calculate Schwartz Formula &lt; 80 mL/min/1.73 m2 ( 1.33 mL/s ) , subject &gt; = 18 year estimate glomerular filtration rate ( eGFR ) calculate MDRD Formula &lt; 60 mL/min/1.73 m2 ( 1.33 mL/s ) 10 . Presence either : antibody glutamic acid decarboxylase ( GAD ) protein tyrosine phosphataselike protein antibody ( IA2 ) 11 . An abnormal TSH value screen evaluate free T4 . Subjects abnormal free T4 value exclude 12 . Hematuria ( confirm microscopy screen ) explanation judge investigator randomization 13 . Anemia etiology define hemoglobin &lt; =10.7 g/dL ( 107 g/L ) females &lt; = 11.3 g/dL ( 113 g/L ) male . Subjects consider anemia accord local guideline exclude 14 . Volumedepleted subject . Subjects risk volume depletion due coexist condition concomitant medication , loop diuretic , carefully monitor volume status</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>